Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001628280-16-011139
Filing Date
2016-02-16
Accepted
2016-02-12 17:31:18
Documents
1

Document Format Files

Seq Description Document Type Size
1 SC 13G schedule13gajkazimi2015.htm SC 13G 75985
  Complete submission text file 0001628280-16-011139.txt   77481
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filed by) CIK: 0001087294 (see all company filings)

EIN.: 000000000
Type: SC 13G
SIC: 2834 Pharmaceutical Preparations

Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Subject) CIK: 0001087294 (see all company filings)

EIN.: 000000000
Type: SC 13G | Act: 34 | File No.: 005-85205 | Film No.: 161421120
SIC: 2834 Pharmaceutical Preparations